Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical ...

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month. Magargee has been serving ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that its phase IIb study of Prasinezumab in early-stage Parkinson's disease missed the primary endpoint, but data suggested ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s ...

SOUTH SAN FRANCISCO, Calif., December 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating ...

7:53 PM ESTHealth Care Genentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to match Genentech parent Roche has cut 20% of risky drugs from pipeline and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage ...